OPGN A Tale Of 2 FibsOPGN has slowly crept up ever since that insider buying in June. After meandering around the 786 fib line for weeks, the stock finally headed back toward that 618 fib line and...yet again...was rejected at that level. In general, momentum has been building in the stock but now with some attention, this 618 fib level could be an important one to keep an eye on for longs. You've also got the FDA review to think about as well.
From June:
" The company recently submitted an updated 510(k) summary to the FDA for its Acuitas AMR Gene Panel for isolates. It included all of the FDA’s previously requested updates and consistent with the FDA’s outlined timeline. OpGen was previously informed that the FDA intends to complete its review by the end of August ...Obviously, with infectious diseases taking up a lot of the news flow over the last year, diagnostics companies have grown in popularity. Along with subsidiaries Curetis GmbH and Ares Genetics GmbH, OpGen develops and commercializes molecular microbiology solutions to guide clinicians with rapid and actionable information about life-threatening infections...One of the main catalysts for this week is actually based on insider activity. A few Form 4s were filed on the 14th, showing insider buys this month. Both COO Johannes Bacher and CEO Oliver Schacht picked up a total of 40,000 shares for just over $90,000. Purchases were made at prices ranging from $2.22 to $2.30. "
Quote Source & Read More: 5 Top Penny Stocks Insiders Decided To Buy In June 2021
Opgnchart
OPGN Would you buy something that was 1000x more expensive? 6/9/2020 Alliance Global Partners Reiterated Rating to Buy and target price to $5.00
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease.
Aug 11 Reuters:
OpGen Group Company Ares Genetics Demonstrates Feasibility of CLIA-compliant Next Generation Sequencing Workflow for Identification of Bacterial Pathogens and Antibiotic Resistance Markers
Aug 9 Reuters:
OpGen Co-Markets COVID-19 Antibody Test Kit.
OpGen is marketing and promoting the CELLSEARCH system, CELLSEARCH CEC kit, and certain COVID-19 related products that are sold and distributed by MSB on a non-exclusive basis
Market cap. 34.511M
Net income: -12.446M
Annual Sales $3.50 million
If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
OPGN. P-Modeling Pt X. The Cajun's of Hyperspace TravelWelcome Hyperspace Traveler!
This is Trial X on OPGN.
Trial X is special.
Come join me...
This would be a great place to reverse. ^evil smile^.
Let's see how this goes!
Start//: Before Snapshot.
End//: After Snapshot.
45 minute TF>
Massive Harmonic Suppression..
Amplification imminent.
This model adheres to Time-Series
Failure is a necessary component of success.
Entry Avg $2.70- $3.48 @12,100 shares.
Target: $38.00 -$41.00
Knife Catch: ??
When:> Before April 20th.
Approx Profit if Quantum Model is followed: $459,800 - $496,000
Why?
Catalyst: Corvid-19 test kits, Merger, FDA approval, Diagnostics.
Come for the laughs,
Stay for the Art.
____________________________
If you are lurking, let me know.
Thanks for Pondering the Unknown with Me,
Glitch420
